Page last updated: 2024-11-13
taccalonolide e
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
taccalonolide E: has microtubule-stabilizing activity; isolated from Tacca chantrieri; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 56672430 |
CHEMBL ID | 1821840 |
SCHEMBL ID | 16273055 |
MeSH ID | M0452060 |
Synonyms (3)
Synonym |
---|
taccalonolide e |
CHEMBL1821840 |
SCHEMBL16273055 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (16)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID617741 | Toxicity in B6C3F1 mouse allografted with mouse 16/C cells assessed as mean body weight loss at 54 mg/kg, iv administered on days 1,4,6, 8, 9, 10 and 11 (Rvb = -2.2%) | 2011 | Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17 | Identification and biological activities of new taccalonolide microtubule stabilizers. |
AID617645 | Antitumor activity against mouse 16/C cells allografted in mouse B6C3F1 assessed as decrease in tumor mass at 90 mg/kg, iv administered on days 1,4,6, 8, 9, 10 and 11 relative to control | 2011 | Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17 | Identification and biological activities of new taccalonolide microtubule stabilizers. |
AID617743 | Toxicity in B6C3F1 mouse allografted with mouse 16/C cells assessed as lethality at 54 mg/kg, iv administered on days 1,4,6, 8, 9, 10 and 11 measured after 12 days relative to control | 2011 | Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17 | Identification and biological activities of new taccalonolide microtubule stabilizers. |
AID617548 | Induction of interphase microtubule bundling in human HeLa cells at 2.5 uM after 18 hrs by indirect immunofluorescence analysis | 2011 | Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17 | Identification and biological activities of new taccalonolide microtubule stabilizers. |
AID617635 | Cell cycle arrest in human HeLa cells assessed as accumulation of cells at G2/M phase at 2.5 uM after 18 hrs by flow cytometric analysis | 2011 | Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17 | Identification and biological activities of new taccalonolide microtubule stabilizers. |
AID617734 | Antitumor activity against mouse 16/C cells allografted in mouse B6C3F1 assessed as gross log cell killing at 54 mg/kg, iv administered on days 1,4,6, 8, 9, 10 and 11 relative to control | 2011 | Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17 | Identification and biological activities of new taccalonolide microtubule stabilizers. |
AID617742 | Toxicity in B6C3F1 mouse allografted with mouse 16/C cells assessed as lethality at 90 mg/kg, iv administered on days 1,4,6, 8, 9, 10 and 11 measured after 12 days relative to control | 2011 | Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17 | Identification and biological activities of new taccalonolide microtubule stabilizers. |
AID762819 | Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay | 2013 | Journal of natural products, Jul-26, Volume: 76, Issue:7 | Hydrolysis reactions of the taccalonolides reveal structure-activity relationships. |
AID617733 | Antitumor activity against mouse 16/C cells allografted in mouse B6C3F1 assessed as gross log cell killing at 90 mg/kg, iv administered on days 1,4,6, 8, 9, 10 and 11 relative to control | 2011 | Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17 | Identification and biological activities of new taccalonolide microtubule stabilizers. |
AID617740 | Toxicity in B6C3F1 mouse allografted with mouse 16/C cells assessed as mean body weight loss at 90 mg/kg, iv administered on days 1,4,6, 8, 9, 10 and 11 (Rvb = -2.2%) | 2011 | Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17 | Identification and biological activities of new taccalonolide microtubule stabilizers. |
AID617726 | Antitumor activity against mouse 16/C cells allografted in mouse B6C3F1 assessed as delay in tumor growth at 90 mg/kg, iv administered on days 1,4,6, 8, 9, 10 and 11 relative to control | 2011 | Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17 | Identification and biological activities of new taccalonolide microtubule stabilizers. |
AID1180503 | Antiproliferative activity against human HeLa cells by SRB assay | 2014 | Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14 | Synthetic reactions with rare taccalonolides reveal the value of C-22,23 epoxidation for microtubule stabilizing potency. |
AID617727 | Antitumor activity against mouse 16/C cells allografted in mouse B6C3F1 assessed as delay in tumor growth at 54 mg/kg, iv administered on days 1,4,6, 8, 9, 10 and 11 relative to control | 2011 | Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17 | Identification and biological activities of new taccalonolide microtubule stabilizers. |
AID616233 | Inhibition of beta tubulin in human HeLa cells assessed asultiple abnormal mitotic spindle formation at 2.5 uM after 18 hrs by immunofluorescence analysis | 2011 | Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17 | Identification and biological activities of new taccalonolide microtubule stabilizers. |
AID617646 | Antitumor activity against mouse 16/C cells allografted in mouse B6C3F1 assessed as decrease in tumor mass at 54 mg/kg, iv administered on days 1,4,6, 8, 9, 10 and 11 relative to control | 2011 | Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17 | Identification and biological activities of new taccalonolide microtubule stabilizers. |
AID617639 | Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay | 2011 | Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17 | Identification and biological activities of new taccalonolide microtubule stabilizers. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.51
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.51) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (14.29%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (85.71%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |